Form 4: Mineralys Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc., sold 416 shares of common stock on July 17, 2026 for $26.53 per share.
Summary
- Option exercise/conversion: acquired 416 Common Stock at $15.44 ($6,423) on July 17, 2026; holds 51,800 after (Direct).
- Open-market sale: disposed of 416 Common Stock at $26.53 ($11,036) on July 17, 2026; holds 51,384 after (Direct).
- Option exercise/conversion: disposed of 416 Stock Option on July 17, 2026; holds 3,334 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $11,036 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
David Malcom Rodman — Officer (Chief Medical Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-17 | Option exercise/conversion | Common Stock | 416 | $15 | $6.4K | 51,800 |
| 2026-07-17 | Open-market sale | Common Stock | 416 | $27 | $11.0K | 51,384 |
| 2026-07-17 | Option exercise/conversion | Stock Option | 416 | — | — | 3,334 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-17 | Option exercise/conversion (416 shares) |
| 2026-07-17 | Open-market sale (416 shares) |
| 2026-07-17 | Option exercise/conversion (416 shares) |
Keywords
insider transaction, Form 4, MLYS, Mineralys Therapeutics, Inc., bearish, David Malcom Rodman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.